Scarica l'app Stockscreener
58.72
0.93%
0.54
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$58.18
Aprire:
$57.81
Volume 24 ore:
255.00K
Relative Volume:
0.70
Capitalizzazione di mercato:
$2.04B
Reddito:
-
Utile/perdita netta:
$-91.00M
Rapporto P/E:
-16.00
EPS:
-3.67
Flusso di cassa netto:
$-74.38M
1 W Prestazione:
-3.90%
1M Prestazione:
+1.64%
6M Prestazione:
+8.04%
1 anno Prestazione:
+17.56%
Intervallo 1D:
$57.54
$59.02
Intervallo di 1 settimana:
$57.54
$64.83
Portata 52W:
$30.82
$68.73
Disc Medicine Inc Stock (IRON) Company Profile
Nome
Disc Medicine Inc
Settore
Industria
Telefono
(617) 674-9274
Indirizzo
321 ARSENAL STREET, SUITE 101, WATERTOWN
Confronta IRON con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
58.72 | 2.05B | 0 | -91.00M | -74.38M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.36 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.01 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.31 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.97 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.33 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-11 | Ripresa | Raymond James | Strong Buy |
| 2025-02-27 | Iniziato | TD Cowen | Buy |
| 2024-11-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-04 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-23 | Iniziato | Jefferies | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-22 | Iniziato | Wells Fargo | Overweight |
| 2024-04-01 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2023-12-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-06-09 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-06-07 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-17 | Iniziato | Raymond James | Outperform |
| 2023-04-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-21 | Iniziato | Stifel | Buy |
| 2023-04-20 | Iniziato | Morgan Stanley | Overweight |
| 2023-03-23 | Iniziato | BMO Capital Markets | Outperform |
| 2023-02-28 | Iniziato | SVB Securities | Outperform |
Mostra tutto
Disc Medicine Inc Borsa (IRON) Ultime notizie
Morgan Stanley Assumes Coverage of Disc Medicine (IRON) With $85 PT - MSN
Can Disc Medicine Inc. Bounce Back From Weekly LowWeekly Volume Report & Technical Pattern Alert System - classian.co.kr
Is Disc Medicine Inc. in a long term uptrendJuly 2025 Rallies & Real-Time Chart Pattern Alerts - newsyoung.net
Bitterman Kevin, director at Disc Medicine, sells $1.96m in iron stock - Investing.com Canada
Disc Medicine’s (IRON) Rising Net Losses Could Be a Game Changer for Its Financial Strategy - simplywall.st
Disc Medicine Inc. Stocks Attracting Dip BuyersEarnings Recap Report & Target Return Focused Stock Picks - beatles.ru
Disc Medicine,Inc. shares rise 2.40% intraday after BioRestorative Therapies reported Q2 2025 financial results and clinical program milestones. - AInvest
Disc Medicine Reports Q2 2025 Financial Results and Clinical Progress - TipRanks
Disc Medicine (IRON) Q2 Loss Widens 109% - AOL.com
Disc Medicine Director Bitterman Kevin Sells 395 Shares at $60.95/Share on 08/05/2025. - AInvest
Disc Medicine: Strong Financial Position and Promising Drug Pipeline Justify Buy Rating - TipRanks
Disc Medicine Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Disc Medicine Misses On Losses But Keeps Wall Street Optimistic - Finimize
Disc Medicine Stumbles On Earnings But Analysts Stay Bullish - Finimize
Disc Medicine (IRON) Q2 Loss Widens 109% - The Motley Fool
Disc Medicine Shares Fall After Wider-Than-Expected Q2 Loss - MarketScreener
Disc Medicine reports Q2 EPS ($1.58), consensus ($1.14) - TipRanks
Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Disc Medicine, Inc. SEC 10-Q Report - TradingView
Disc Medicine Q2 loss bigger than expected as costs increase - TradingView
Disc Medicine Earnings: FDA Filing Timeline Set for EPP Drug as Cash Reserves Hit $650M Milestone - Stock Titan
How strong is Disc Medicine Inc. company’s balance sheetInvest confidently with real-time market updates - Jammu Links News
Is Disc Medicine Inc. a good long term investmentDiscover dynamic stocks ready to soar - Jammu Links News
Is it the right time to buy Disc Medicine Inc. stockMarket-leading growth rates - Jammu Links News
What catalysts could drive Disc Medicine Inc. stock higher in 2025Achieve consistent double-digit growth - Jammu Links News
What analysts say about Disc Medicine Inc. stockMaximize portfolio growth with professional advice - Jammu Links News
Is Disc Medicine Inc. a growth stock or a value stockMarket-beating performance - Jammu Links News
Published on: 2025-08-03 11:24:58 - Jammu Links News
What are analysts’ price targets for Disc Medicine Inc. in the next 12 monthsBuild a winning investment strategy today - Jammu Links News
How many analysts rate Disc Medicine Inc. as a “Buy”Realize exceptional returns through smart trading - Jammu Links News
How does Disc Medicine Inc. generate profit in a changing economyHigh-octane investment opportunities await - Jammu Links News
Insider Selling at Disc Medicine Inc.: A Signal or a Symptom? - AInvest
Is Disc Medicine Inc. stock overvalued or undervaluedLow Risk Report For Consistent Profits - Jammu Links News
Institutional Investors in Disc Medicine, Inc. (NASDAQ:IRON) See US$140m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them. - 富途牛牛
Why Disc Medicine Inc. stock attracts strong analyst attentionNews Based Entry Opportunity Alerts Detected - metal.it
How does Disc Medicine Inc. compare to its industry peersExpert Picks Watchlist For 2025 - Jammu Links News
Disc Medicine's NDA Submission for Bitopertin in EPP: A High-Probability Catalyst for Value Creation - AInvest
Disc Medicine, Inc. (IRON) Set to Submit NDA for Bitopertin in October 2025 - Insider Monkey
What is the dividend policy of Disc Medicine Inc. stockMaximize gains with strategic stock entries - Jammu Links News
Are Investors Undervaluing Disc Medicine, Inc. (NASDAQ:IRON) By 49%? - Yahoo Finance
How volatile is Disc Medicine Inc. stock compared to the marketBreakneck growth rates - jammulinksnews.com
Disc Medicine Inc Azioni (IRON) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Disc Medicine Inc Azioni (IRON) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bitterman Kevin | Director |
Aug 14 '25 |
Sale |
60.99 |
7,212 |
439,860 |
592,908 |
2.44%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):